Page last updated: 2024-12-10

arachidonoyl amine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

arachidonoyl amine : A primary fatty amide resulting from the formal condensation of the carboxy group of arachidonic acid with ammonia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5283393
CHEMBL ID15150
CHEBI ID137830
SCHEMBL ID542346

Synonyms (36)

Synonym
BRD-K29555132-001-02-2
BCBCMAP01_000148
BSPBIO_001537
IDI1_034007
arachidonoyl amine
NCGC00161187-05
NCGC00161187-03
NCGC00161187-04
NCGC00161187-06
CHEBI:137830
HMS1989M19
arachidonamide
CHEMBL15150 ,
BML2-C08
HMS1791M19
HMS1361M19
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid amide
bdbm50056489
5z,8z,11z,14z-eicosatetraenoyl amine
LMFA08010007
arachidonoylamide
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenamide
85146-53-8
SCHEMBL542346
5z,8z,11z,14z-eicosatetraenamide
arachidonoyl amide
BNBSCAZCQDLUDU-DOFZRALJSA-N
HMS3402M19
HMS3650G07
arachidonamide (20:4, n-6)
sr-01000946782
SR-01000946782-1
5(z),8(z),11(z),14(z)-eicosatetraenamide
arachidonamide(20:4,n-6)
arachidonic acid amide
DTXSID001347885
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
cannabinoid receptor agonistAn agonist that binds to and activates cannabinoid receptors.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
primary fatty amideA primary carboxamide RC(=O)NH2 resultng from the formal condensation of the carboxy group of a fatty acid with ammonia.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki6.73330.00020.566510.0000AID49668; AID49674
Cannabinoid receptor 1Homo sapiens (human)Ki9.60000.00010.50779.6000AID49311
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Rattus norvegicus (Norway rat)Km2.34002.34002.56002.7800AID38666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (34)

Processvia Protein(s)Taxonomy
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID49668In vitro binding affinity was determined against rat brain Cannabinoid receptor 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
AID38685Tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID196759Inhibition of rat glial cell gap junction at the concentration of 50 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID38666Km value for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID38682Tested for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID232843Ratio of Vmax value and Km value of the compound.1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID387967Antiproliferative activity against human WI38 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
AID38683V max value for hydrolysis by rat brain microsomal anandamide amidohydrolase (AAH).1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID196758Tested for inhibition of rat glial cell gap junction at the concentration of 20 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID49311Binding affinity against the cloned human Cannabinoid receptor 11997Journal of medicinal chemistry, Feb-28, Volume: 40, Issue:5
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
AID49674Tested for binding affinity to Cannabinoid receptor 11999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase.
AID387968Antiproliferative activity against mouse RAW264.7 cells at 10 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry, Nov-15, Volume: 16, Issue:22
Acylamido analogs of endocannabinoids selectively inhibit cancer cell proliferation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.36 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]